News - Page 157 - Psychedelic Alpha

Introducing The Psychedelic Practitioner, a new publication by Psychedelic Alpha.

Read more about the article Psychedelic Bulletin: Compass Pathways Secures 5th Patent; atai to Develop Salvinorin A

Psychedelic Bulletin: Compass Pathways Secures 5th Patent; atai to Develop Salvinorin A

Post published:August 13, 2021
Post category:Psychedelic Bulletin

Read more about the article Cybin Announces Additional Adelia Milestone Achievements

Cybin Announces Additional Adelia Milestone Achievements

Post published:August 12, 2021
Post category:Press Release

Read more about the article Bexson Biomedical Launches New Project, Applying Subcutaneous Delivery Technology To Multiple Psychedelic Compounds For Therapeutic Use

Bexson Biomedical Launches New Project, Applying Subcutaneous Delivery Technology To Multiple Psychedelic Compounds For Therapeutic Use

Post published:August 12, 2021
Post category:Press Release

Read more about the article Psilera Initiates Landmark Preclinical Studies with New Psychedelic Derivatives aimed at Reducing Alcohol Consumption

Psilera Initiates Landmark Preclinical Studies with New Psychedelic Derivatives aimed at Reducing Alcohol Consumption

Post published:August 12, 2021
Post category:Press Release

Read more about the article MindMed Announces 2021 Q2 Financial Results; Cash Balance of $157 USD Million ($195 CAD Million) to Execute on Diverse Clinical Pipeline

MindMed Announces 2021 Q2 Financial Results; Cash Balance of $157 USD Million ($195 CAD Million) to Execute on Diverse Clinical Pipeline

Post published:August 12, 2021
Post category:Press Release

Read more about the article atai Launches Revixia Life Sciences to Develop Salvinorin A for a Variety of Mental Health Conditions

atai Launches Revixia Life Sciences to Develop Salvinorin A for a Variety of Mental Health Conditions

Post published:August 12, 2021
Post category:Press Release

Read more about the article Awakn Life Sciences Begins Trading on the OTCQB(R) Venture Market Under the Symbol ‘AWKNF’ on August 12th

Awakn Life Sciences Begins Trading on the OTCQB(R) Venture Market Under the Symbol ‘AWKNF’ on August 12th

Post published:August 12, 2021
Post category:Press Release

Read more about the article Wesana Health Commences Functional Animal Study for Treatment of Traumatic Brain Injury

Wesana Health Commences Functional Animal Study for Treatment of Traumatic Brain Injury

Post published:August 11, 2021
Post category:Press Release

Read more about the article COMPASS Pathways plc announces financial results and business highlights for the second quarter 2021

COMPASS Pathways plc announces financial results and business highlights for the second quarter 2021

Post published:August 11, 2021
Post category:Press Release

Read more about the article MYND Life Sciences Announces DTC Eligibility

MYND Life Sciences Announces DTC Eligibility

Post published:August 11, 2021
Post category:Press Release

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.